

Title (en)

METHOD AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER

Title (de)

METHODEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG HEPATOZELLULÄREN KREBSSES

Title (fr)

METHODES ET COMPOSITIONS DESTINEES AU TRAITEMENT DU CANCER HEPATOCELLULAIRE

Publication

EP 1253930 A4 20030521 (EN)

Application

EP 01910587 A 20010212

Priority

- US 0104539 W 20010212
- US 18196600 P 20000210
- US 66025200 A 20000912
- US 66250500 A 20000914

Abstract (en)

[origin: WO0158922A2] A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule, where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells. A composition for preventing or for treating cancer comprising a peptide having at least part of the sequence of alpha fetoprotein.

IPC 1-7

A61K 38/00; **A61K 38/04**; **A61K 39/00**; **A61K 45/00**; **A61K 48/00**; **C07H 21/04**; **C07K 2/00**; **C07K 4/12**; **C07K 7/06**; **C12N 5/08**; **C12N 15/11**

IPC 8 full level

C12N 15/00 (2006.01); **A61K 35/12** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/39** (2006.01); **A61P 1/16** (2006.01); **A61P 35/00** (2006.01); **A61P 37/04** (2006.01); **C07K 14/47** (2006.01); **C07K 14/82** (2006.01)

CPC (source: EP KR)

A61K 38/00 (2013.01 - KR); **A61K 39/4615** (2023.05 - EP KR); **A61K 39/4622** (2023.05 - EP KR); **A61K 39/4644** (2023.05 - EP KR); **A61K 39/464481** (2023.05 - EP KR); **A61P 1/16** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **C07K 14/4715** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **A61K 39/00** (2013.01 - EP KR); **A61K 2239/31** (2023.05 - EP KR); **A61K 2239/38** (2023.05 - EP KR); **A61K 2239/53** (2023.05 - EP KR)

Citation (search report)

[T] BUTTERFIELD L H ET AL: "T cell responses to HLA-A* 0201-restricted peptides derived from human [alpha] fetoprotein", JOURNAL OF IMMUNOLOGY 15 APR 2001 UNITED STATES, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 5300 - 5308, XP002235963, ISSN: 0022-1767

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0158922 A2 20010816; **WO 0158922 A3 20020214**; **WO 0158922 A9 20021017**; AU 3817901 A 20010820; CN 1255427 C 20060510; CN 1398187 A 20030219; EP 1253930 A2 20021106; EP 1253930 A4 20030521; HK 1046853 A1 20030130; JP 2003522195 A 20030722; JP 3876162 B2 20070131; KR 100482920 B1 20050414; KR 20020073203 A 20020919

DOCDB simple family (application)

US 0104539 W 20010212; AU 3817901 A 20010212; CN 01804758 A 20010212; EP 01910587 A 20010212; HK 02108331 A 20021118; JP 2001558069 A 20010212; KR 20027010174 A 20020807